4.8 Article

Tumor cell-targeting radiotherapy in the treatment of glioblastoma multiforme using linear accelerators

Journal

ACTA BIOMATERIALIA
Volume 125, Issue -, Pages 300-311

Publisher

ELSEVIER SCI LTD
DOI: 10.1016/j.actbio.2021.02.019

Keywords

Targeted sensitization-enhanced; radiotherapy; GBM treatment; Low-dose radiotherapy; 5-ALA; radioenhancer

Funding

  1. Ministry of Science and Technology [MOST-107-2823-8-010-002, MOST-108 -2314-B-010-035-MY3]
  2. Far Eastern Memorial Hospital [106DN21]

Ask authors/readers for more resources

TSER is a strategy for achieving precision cell-targeted radiotherapy using common linear accelerators, involving a combination of GoldenDisk, 5-ALA, low-intensity ultrasound, and low-dose radiation therapy. It exhibited synergized radiosensitization effects and showed enhanced therapeutic effect and survival in the treatment of an orthotropic GBM model with only 20% of the radiation dose.
Although boron neuron capture therapy (BNCT) has enabled the delivery of stronger radiation dose to glioblastoma multiforme (GBM) cells for precision radiotherapy (RT), patients in need are almost unable to access the treatment due to insufficient operating devices. Therefore, we developed targeted sensitization-enhanced radiotherapy (TSER), a strategy that could achieve precision cell-targeted RT using common linear accelerators. TSER, which involves the combination of GoldenDisk (GD; a spherical radioenhancer), 5-aminolevulinic acid (5-ALA), low-intensity ultrasound (US), and low-dose RT, exhibited synergized radiosensitization effects. Both 5-ALA and hyaluronic-acid-immobilized GD can selectively accumulate in GBM to induce chemical and biological enhancement of radiosensitization, resulting in DNA damage, escalation of reactive oxygen species levels, and cell cycle redistribution, in turn sensitizing GBM cells to radiation under US. TSER showed an enhanced therapeutic effect and survival in the treatment of an orthotropic GBM model with only 20% of the radiation dose compared to that of a 10-Gy RT. The strategy with the potential to inhibit GBM progress and rescue the organ at risk using low-dose RT, thereby improving the quality of life of GBM patients, shedding light on achieving cell-targeted RT using universally available linear accelerators. Statement of significance We invented GoldenDisk (GD), a radioenhancer with hyaluronic-acid (HAc)-coated gold nanoparticle (AuNP)-core/silica shell nanoparticle, to make radiotherapy (RT) safer and smarter. The surface modification of HAc and silica allows GD to target CD44-overexpressed glioblastoma multiforme (GBM) cells and stay structurally stable in cytoplasm throughout the course of RT. By combining GD with low-energy ultrasound and an FDA-approved imaging agent, 5-aminolevulinic acid (5-ALA), GBM cells were sensitized to RT leaving healthy tissues in the vicinity unaffected. The ionized radiation can further be transferred to photoelectronic products with higher cytotoxicity by GD upon collision, achieving higher therapeutic efficacy. With the newly-developed strategy, we are able to achieve low-dose precision RT with the use of only 20% radiation dose. ? 2021 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available